InvestorsHub Logo

alphapuppy

02/13/24 8:42 AM

#671802 RE: manibiotech #671799

Mani you are correct absolutely nothing has the ability to impact share price. Absolutely nothing.

We’ve already had so many great things like the jam article, survival advantage, no, side effects, Eden, etc. etc. etc. and nothing, Nada, absolutely nil effect on value and share price. So absolutely, the nature article will have no effect as well. Nothing does nothing can. KG has it pretty well locked down forever.

And management will never partner will never ask for help. Will never do anything like that. Control freaks it seems.

Doc logic

02/13/24 9:13 PM

#671994 RE: manibiotech #671799

manibiotech,

The journal article will attract a few more eyes and interest. Not until NWBO proves they are worth what they are asking with expected revenues and ability to move forward rapidly or big pharma is ready to partner with approval and automated manufacturing in place will the price rise accordingly. Until that time checkpoint inhibitor sales will continue to climb without the need to offer deference to the DCVax platform. When the investment community realizes that big pharma will be forced into deference then the tables turn. Big pharma will try to keep this from happening by timing their agreement(s). Linda has her timing involved too so it’s likely that the longer it takes for an agreement, unless already agreed to in principle at a certain milestone point, the more likely the agreement will be for bigger numbers. Seems likely there is a milestone trigger moment but Linda does have options ; ). Best wishes.